Cargando…

Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors

BACKGROUND: China’s national tuberculosis programme does not have cohort wise information regarding attrition and delays in the multidrug resistant tuberculosis (MDR-TB) diagnosis and treatment pathway. OBJECTIVE: Under the Global Fund programmatic management of drug-resistant TB (2006–13), we asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Caihong, Li, Renzhong, Shewade, Hemant Deepak, Jeyashree, Kathiresan, Ruan, Yunzhou, Zhang, Canyou, Wang, Lixia, Zhang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453446/
https://www.ncbi.nlm.nih.gov/pubmed/30958841
http://dx.doi.org/10.1371/journal.pone.0214943
_version_ 1783409397662220288
author Xu, Caihong
Li, Renzhong
Shewade, Hemant Deepak
Jeyashree, Kathiresan
Ruan, Yunzhou
Zhang, Canyou
Wang, Lixia
Zhang, Hui
author_facet Xu, Caihong
Li, Renzhong
Shewade, Hemant Deepak
Jeyashree, Kathiresan
Ruan, Yunzhou
Zhang, Canyou
Wang, Lixia
Zhang, Hui
author_sort Xu, Caihong
collection PubMed
description BACKGROUND: China’s national tuberculosis programme does not have cohort wise information regarding attrition and delays in the multidrug resistant tuberculosis (MDR-TB) diagnosis and treatment pathway. OBJECTIVE: Under the Global Fund programmatic management of drug-resistant TB (2006–13), we assessed the attrition and delay in the pathway and the factors associated. METHODS: Cohort study involving secondary programme data. All patients identified as presumptive MDR-TB (defined as i) previously treated TB patients which included recurrent TB, return after loss to follow up, treatment after failure and ii) new TB patients that were non-converters at three months of treatment or in close contact with a known MDR-TB patient) during October 2006 to June 2013 were eligible for phenotypic drug susceptibility testing (DST). Pre-diagnosis attrition (presumptive MDR-TB not undergoing culture and DST) and pre-treatment attrition (confirmed MDR-TB patients not initiated on treatment) was calculated. Diagnosis delay was the time interval from DST eligibility to DST result, treatment initiation delay was fom DST result to treatment initiation and total delay was from DST eligbility to treatment initiation. Factors associated with attrition and delay were identified using log binomial regression and linear regression, respectively. RESULTS: Of 78 564 presumptive MDR-TB patients, 2 470 (3.1%) underwent pre-diagnosis attrition. Of 9 283 MDR-TB patients, 3 361 (36.2%) underwent pre-treatment attrition. Median(IQR) diagnosis delay was 84 (64, 114) days; treatment initation delay was 23(6,68) days and total delay was 117(77,187) days. Long diagnosis delay was an independent predictor of pre-treatment attrition in a dose response relationship. While pre-treatment attrition was less likely among presumptive criterion ‘previously treated’ and with increasing time period, it was more likey among elderly and in east and west region. While the diagnosis delay increased with time period, treatment initiation delay and total delay reduced with time period. Short diagnosis delay was associated with west region, smear negative patients and presumptive criterion ‘treatment after lost to follow up’. Short treatment initiation delay was associatied with east and west regions while long treatment initiation delay was associated with elderly and presumptive criterion ‘recurrent TB’. Total delay predictors were similar to treatment initiation delay. In addition, short total delay was associated with presumptive criterion ‘treatment after failure’. CONCLUSION: The diagnosis and treatment delay were long and the pre-treatment attrition was considerable high. Long diagnosis delay is likely to predict pre-treatment attrition.
format Online
Article
Text
id pubmed-6453446
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-64534462019-04-19 Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors Xu, Caihong Li, Renzhong Shewade, Hemant Deepak Jeyashree, Kathiresan Ruan, Yunzhou Zhang, Canyou Wang, Lixia Zhang, Hui PLoS One Research Article BACKGROUND: China’s national tuberculosis programme does not have cohort wise information regarding attrition and delays in the multidrug resistant tuberculosis (MDR-TB) diagnosis and treatment pathway. OBJECTIVE: Under the Global Fund programmatic management of drug-resistant TB (2006–13), we assessed the attrition and delay in the pathway and the factors associated. METHODS: Cohort study involving secondary programme data. All patients identified as presumptive MDR-TB (defined as i) previously treated TB patients which included recurrent TB, return after loss to follow up, treatment after failure and ii) new TB patients that were non-converters at three months of treatment or in close contact with a known MDR-TB patient) during October 2006 to June 2013 were eligible for phenotypic drug susceptibility testing (DST). Pre-diagnosis attrition (presumptive MDR-TB not undergoing culture and DST) and pre-treatment attrition (confirmed MDR-TB patients not initiated on treatment) was calculated. Diagnosis delay was the time interval from DST eligibility to DST result, treatment initiation delay was fom DST result to treatment initiation and total delay was from DST eligbility to treatment initiation. Factors associated with attrition and delay were identified using log binomial regression and linear regression, respectively. RESULTS: Of 78 564 presumptive MDR-TB patients, 2 470 (3.1%) underwent pre-diagnosis attrition. Of 9 283 MDR-TB patients, 3 361 (36.2%) underwent pre-treatment attrition. Median(IQR) diagnosis delay was 84 (64, 114) days; treatment initation delay was 23(6,68) days and total delay was 117(77,187) days. Long diagnosis delay was an independent predictor of pre-treatment attrition in a dose response relationship. While pre-treatment attrition was less likely among presumptive criterion ‘previously treated’ and with increasing time period, it was more likey among elderly and in east and west region. While the diagnosis delay increased with time period, treatment initiation delay and total delay reduced with time period. Short diagnosis delay was associated with west region, smear negative patients and presumptive criterion ‘treatment after lost to follow up’. Short treatment initiation delay was associatied with east and west regions while long treatment initiation delay was associated with elderly and presumptive criterion ‘recurrent TB’. Total delay predictors were similar to treatment initiation delay. In addition, short total delay was associated with presumptive criterion ‘treatment after failure’. CONCLUSION: The diagnosis and treatment delay were long and the pre-treatment attrition was considerable high. Long diagnosis delay is likely to predict pre-treatment attrition. Public Library of Science 2019-04-08 /pmc/articles/PMC6453446/ /pubmed/30958841 http://dx.doi.org/10.1371/journal.pone.0214943 Text en © 2019 Xu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Xu, Caihong
Li, Renzhong
Shewade, Hemant Deepak
Jeyashree, Kathiresan
Ruan, Yunzhou
Zhang, Canyou
Wang, Lixia
Zhang, Hui
Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors
title Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors
title_full Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors
title_fullStr Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors
title_full_unstemmed Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors
title_short Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors
title_sort attrition and delays before treatment initiation among patients with mdr-tb in china (2006-13): magnitude and risk factors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453446/
https://www.ncbi.nlm.nih.gov/pubmed/30958841
http://dx.doi.org/10.1371/journal.pone.0214943
work_keys_str_mv AT xucaihong attritionanddelaysbeforetreatmentinitiationamongpatientswithmdrtbinchina200613magnitudeandriskfactors
AT lirenzhong attritionanddelaysbeforetreatmentinitiationamongpatientswithmdrtbinchina200613magnitudeandriskfactors
AT shewadehemantdeepak attritionanddelaysbeforetreatmentinitiationamongpatientswithmdrtbinchina200613magnitudeandriskfactors
AT jeyashreekathiresan attritionanddelaysbeforetreatmentinitiationamongpatientswithmdrtbinchina200613magnitudeandriskfactors
AT ruanyunzhou attritionanddelaysbeforetreatmentinitiationamongpatientswithmdrtbinchina200613magnitudeandriskfactors
AT zhangcanyou attritionanddelaysbeforetreatmentinitiationamongpatientswithmdrtbinchina200613magnitudeandriskfactors
AT wanglixia attritionanddelaysbeforetreatmentinitiationamongpatientswithmdrtbinchina200613magnitudeandriskfactors
AT zhanghui attritionanddelaysbeforetreatmentinitiationamongpatientswithmdrtbinchina200613magnitudeandriskfactors